Advanced search
Publication Cover
Leukemia & Lymphoma Volume 56, 2015 - Issue 10
Submit an article Journal homepage
95
Views
0
CrossRef citations to date
0
Altmetric
Commentaries

The rosy future of BCL-2 inhibition in chronic lymphocytic leukemia: pursuit of a worthy target

Jennifer R. Brown Director, CLL Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Department of Medicine, Harvard Medical School, Boston, MA, USACorrespondence[email protected]
Pages 2755-2756 | Published online: 18 Jun 2015

References

  • Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005;435:677–681.
  • Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008;68:3421–3428.
  • Vogler M, Furdas SD, Jung M, et al. Diminished sensitivity of chronic lymphocytic leukemia cells to ABT-737 and ABT-263 due to albumin binding in blood. Clin Cancer Res 2010;16:4217–4225.
  • Wilson WH, O’Connor OA, Czuczman MS, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 2010;11:1149–1159.
  • Roberts AW, Seymour JF, Brown JR, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL-2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 2012;30:488–496.
  • Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013;19:202–208.
  • Kipps TJ, Eradat H, Grosicki S, et al. A phase 2 study of the BH3 mimetic BCL-2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia. Leuk Lymphoma 2015:56:2828–2833.
  • Roberts AW, Ma S, Brander DM, et al. Determination of recommended phase 2 dose of ABT-199 (GDC-0199) combined with Rituximab (R) in patients with Relapsed / Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). Blood 2014;124:325–325.
  • Seymour JF, Davids MS, Pagel JM, et al. ABT-199 (GDC-0199) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia: high response rates among patients with high risk disease features including unmutated IGHV. Haematologica 2014;99(Suppl 1):702.
  • Fresquet V, Rieger M, Carolis C, et al. Acquired mutations in BCL-2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma. Blood 2014;123:4111–4119.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.